MAPT and Alzheimer disease: The levels of NAD+ are reduced in AD animal models, and elevation of cellular NAD+ levels through supplementation with NAD+ precursors such as nicotinamide, nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR) is found to attenuate Aβ and tau pathologies and protect against cognitive dysfunction [233].